Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization

This is a multicenter, prospective cohort study conducted at five sites in China. The study aims to develop and validate a prognostic risk model for major adverse cardiovascular events (MACE) in patients after coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting).

Study population: A total of 600 eligible patients aged ≥18 years who have undergone coronary revascularization will be enrolled consecutively. Key exclusion criteria include severe heart failure, malignant arrhythmias, severe pulmonary or liver/kidney dysfunction, pregnancy, psychiatric disorders, and poor compliance.

Data collection: At baseline (enrollment), the following data are collected: demographics, medical history, surgical characteristics (e.g., access route, number of stents, target vessels), vital signs, laboratory tests (complete blood count, cardiac enzymes, liver/kidney function, lipids, glucose), echocardiography, 24-hour ambulatory electrocardiography, and a standardized Traditional Chinese Medicine (TCM) case report form covering symptom scores, tongue/pulse findings, and pattern elements. In addition, biological samples (blood and tongue coating) are obtained for proteomics, metabolomics, and tongue-coating microbiomics.

Follow-up: Participants are followed at 12, 24, 36, and 48 weeks post-enrollment. At each follow-up, the TCM case report form is reassessed, MACE (including all-cause death, subacute stent thrombosis, perioperative myocardial infarction, recurrent myocardial infarction, recurrent unstable angina, repeat revascularization, and rehospitalization for angina or heart failure) are recorded, and NYHA functional class and current medications are updated.

Statistical analysis: Missing data will be handled by mean imputation or K-nearest neighbors imputation. Continuous variables will be standardized using Z-scores, and categorical variables will be one-hot encoded. Feature selection will be performed using LASSO regression. Three nested prediction models will be built:

* Model\_Base: Cox proportional hazards model based on routine clinical and imaging variables. * Model\_TCM: adding TCM syndrome features using machine learning algorithms (random forest, support vector machine). * Model\_Full: further integrating multi-omics biomarkers using deep learning methods (convolutional neural network, transformer).

Model performance will be assessed by discrimination (area under the ROC curve), calibration, and decision curve analysis. Internal validation will use k-fold cross-validation, and external validation will be conducted in at least three independent hospitals. The targeted predictive accuracy (area under the curve) is above 85%. All analyses will be performed using SPSS 26.0, Python, and R.

Ethics: The study protocol has been approved by the ethics committee of the lead site (The Third Affiliated Hospital of Zhejiang Chinese Medical University) and will be approved by participating centers. Written informed consent will be obtained from all participants.

• Traditional Chinese Medicine (TCM) Syndrome Score [Срок оценки: Baseline, 12, 24, 36, 48 weeks post-enrollment]
• NYHA Functional Class [Срок оценки: 12, 24, 36, 48 weeks post-enrollment]
• Multi-omics Biomarkers (exploratory) [Срок оценки: Baseline]
• Left Ventricular End-Diastolic Diameter (LVEDD) [Срок оценки: Baseline]
• Left Ventricular End-Systolic Diameter (LVESD) [Срок оценки: Baseline]
• Left Ventricular Posterior Wall Thickness (LVPW) [Срок оценки: Baseline]
• Interventricular Septal Thickness (IVS) [Срок оценки: Baseline]
• Left Ventricular Ejection Fraction (LVEF) [Срок оценки: Baseline]
• Left Ventricular Fractional Shortening (FS) [Срок оценки: Baseline]
• E/A Ratio [Срок оценки: Baseline]
• Mean Heart Rate (24-hour) [Срок оценки: Baseline]
• Minimum Heart Rate (24-hour) [Срок оценки: Baseline]